We are live on ! Find out more
ENTX icon

Entera Bio

10 hedge funds and large institutions have $6.54M invested in Entera Bio in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.12% less ownership

Funds ownership: 17.19%17.07% (-0.12%)

17% less funds holding

Funds holding: 1210 (-2)

54% less capital invested

Capital invested by funds: $14.2M → $6.54M (-$7.67M)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
10
Holders Change
-2
Holders Change %
-16.67%
% of All Funds
0.17%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
Increased
1
Reduced
4
Closed
2
Calls
$249K
Puts
Net Calls
+$249K
Net Calls Change
-$301K

ENTX Hedge Fund Activity: Q2 2022 in Review

10 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q2 2022, worth a combined $6.54M — down 54% from $14.2M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ENTX and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $6.1K. The largest seller was Millennium Management, cutting an estimated $65.2K.

  • 10 institutional investors held Entera Bio (ENTX) as of Q2 2022, down from 12 in Q1 2022.
  • Funds reported $6.54M of Entera Bio stock for Q2 2022, down 54% quarter-over-quarter.
  • 0 funds opened new Entera Bio positions in Q2 2022 and 2 closed out, a net change of -2 holders.
  • The largest Entera Bio buyer in Q2 2022 was UBS Group, an estimated $6.1K added.
  • The largest Entera Bio seller in Q2 2022 was Millennium Management, an estimated $65.2K sold.

Based on aggregated 13F filings for Q2 2022.